Revvity RVTY Revenue Breakdown

NYSE RVTY
$148.85 -5.54 (-3.59%)
At close: Nov 16, 2026 · 4:00 PM EST
Annual revenue breakdowns for Revvity, fiscal 2010 to 2025, as reported in its filings.
Annual history

Revvity Revenue by Geography

Years FY 2010–2025
Lines 5
FY 2025 Total $2.86B

United States was Revvity’s largest region in fiscal 2025, bringing in $1.13B of $2.86B (39%).

Revvity revenue by geography, fiscal 2010 to 2025
Geography FY 2010 FY 2011 FY 2012 FY 2012 FY 2013 FY 2014 FY 2016 FY 2017 FY 2017 FY 2018 FY 2019 FY 2021 FY 2022 FY 2023 FY 2023 FY 2024 FY 2025
United States $1.68B $1.55B $1.12B $1.10B $1.13B
Other International $1.34B $1.15B $859.90M $931.71M $1.00B
China $449.59M $476.37M $454.43M $450.01M $425.06M
United Kingdom $357.91M $136.02M $125.42M $112.88M $126.85M
Germany — — $193.17M $162.58M $177.66M
Total $3.83B $3.31B $2.75B $2.76B $2.86B
Totals include 5 discontinued lines from earlier reporting.

Revvity revenue by geography: what the figures show

Revvity brought in $2.86B from its five regions in fiscal 2025, the year ended December 28, 2025. That was up 3.7% from $2.76B in fiscal 2024. United States was the largest at $1.13B (39.4%), ahead of Other International at $1.00B (35.0%) and China at $425.06M (14.9%). The other two regions brought in $304.51M combined.

Compared with fiscal 2024, United Kingdom grew fastest, up 12.4% to $126.85M, while China fell the most, down 5.5% to $425.06M.

Annual history

Revvity Revenue by Major goods/service lines

Years FY 2022–2025
Lines 4
FY 2025 Total $2.86B

Life Sciences Solutions was Revvity’s largest revenue line in fiscal 2025, bringing in $1.19B of $2.86B (42%).

Revvity revenue by major goods/service lines, fiscal 2022 to 2025
Major goods/service lines FY 2022 FY 2023 FY 2023 FY 2024 FY 2025
Life Sciences Solutions — — $1.28B $1.20B $1.19B
Immunodiagnostics $1.80B $1.11B $787.39M $828.63M $869.91M
Reproductive Health $514.86M $516.57M $504.99M $527.80M $555.04M
Software — — $178.29M $200.80M $236.38M
Total $3.83B $3.31B $2.75B $2.76B $2.86B
Totals include 4 discontinued lines from earlier reporting.

Revvity revenue by major goods/service lines: what the figures show

Revvity brought in $2.86B from its four revenue lines in fiscal 2025, the year ended December 28, 2025. That was up 3.7% from $2.76B in fiscal 2024. Life Sciences Solutions was the largest at $1.19B (41.8%), ahead of Immunodiagnostics at $869.91M (30.5%) and Reproductive Health at $555.04M (19.4%). The remaining revenue line, Software, brought in $236.38M.

Compared with fiscal 2024, Software grew fastest, up 17.7% to $236.38M, while Life Sciences Solutions fell the most, down 0.3% to $1.19B.

Revvity began breaking out Life Sciences Solutions in fiscal 2023 and Software in fiscal 2023. Revvity stopped reporting Life Sciences Reagents ($691.34M in fiscal 2023), Life Sciences Instruments ($405.55M in fiscal 2023), Applied Genomics ($393.60M in fiscal 2023) and one other as separate revenue lines.

Annual history

Revvity Revenue by Segment

Years FY 2010–2025
Lines 2
FY 2025 Total $2.86B

Life Sciences was Revvity’s largest segment in fiscal 2025, bringing in $1.43B of $2.86B (50%).

Revvity revenue by segment, fiscal 2010 to 2025
Segment FY 2010 FY 2011 FY 2012 FY 2012 FY 2013 FY 2014 FY 2016 FY 2017 FY 2017 FY 2018 FY 2019 FY 2021 FY 2022 FY 2023 FY 2023 FY 2024 FY 2025
Diagnostics $2.93B $2.02B $1.29B $1.36B $1.42B
Life Sciences $895.87M $1.29B $1.46B $1.40B $1.43B
Total $3.83B $3.31B $2.75B $2.76B $2.86B
Totals include 3 discontinued lines from earlier reporting.

Revvity revenue by segment: what the figures show

Revvity brought in $2.86B from its two segments in fiscal 2025, the year ended December 28, 2025. That was up 3.7% from $2.76B in fiscal 2024. Life Sciences was the largest at $1.43B (50.1%), ahead of Diagnostics at $1.42B (49.9%).

Compared with fiscal 2024, Diagnostics grew 5.1% to $1.42B and Life Sciences grew 2.3% to $1.43B. From fiscal 2022 to 2025, combined revenue from these segments fell from $3.83B to $2.86B, a compound annual decline of 9.3%. Life Sciences' share of the total rose from 23.4% to 50.1%.

Questions

Revvity Revenue Breakdown FAQ

How does Revvity make money?

Revvity (RVTY) reports its revenue by geography, by major goods/service lines and by segment. In fiscal 2025, United States was its largest region, bringing in $1.13B (39.4% of the total), followed by Other International at $1.00B (35.0%).

What is Revvity's largest region?

United States was Revvity's largest region in fiscal 2025, bringing in $1.13B, or 39.4% of the $2.86B total across its five regions.

What is Revvity's largest revenue line?

Life Sciences Solutions was Revvity's largest revenue line in fiscal 2025, bringing in $1.19B, or 41.8% of the $2.86B total across its four revenue lines.

What is Revvity's largest segment?

Life Sciences was Revvity's largest segment in fiscal 2025, bringing in $1.43B, or 50.1% of the $2.86B total across its two segments.

Which Revvity region is growing the fastest?

Among Revvity's regions that make up at least 2% of revenue, United Kingdom grew fastest in fiscal 2025, up 12.4% from $112.88M to $126.85M.

Where does this revenue breakdown data come from?

Every figure comes from Revvity's annual financial filings, as reported. Each line keeps the name Revvity gives it, and years follow its fiscal calendar.

How far back does Revvity's revenue breakdown go?

Revvity's revenue by geography goes back to fiscal 2010, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.